Supplemental Appendix 2: Significant Drug-Drug Interactions

* + Agents independently associated with EPS or OMD
		- Bupropion
		- Chlorpromazine
		- Meclizine
		- Meperidine
		- Methyldopa
		- Metoclopramide
		- Perphenazine
		- Prochlorperazine
		- Promethazine
	+ Agents that could interact with DRBAs via CYP450 (moderate-strong inducers/inhibitors)
		- CYP450 1A2 inducers
			* Phenytoin
			* Rifampin
			* Ritonavir
			* Smoking
			* Teriflunomide
		- CYP450 1A2 inhibitors
			* Ciprofloxacin
			* Enoxacin
			* Ethinyl estradiol
			* Fluvoxamine
			* Methoxsalen
			* Mexiletine
			* Oral contraceptives
			* Zafirlukast
			* Zileuton
		- CYP450 2D6 inhibitors
			* Bupropion
			* Cimetidine
			* Cinacalcet
			* Darifenacin
			* Dronedarone
			* Duloxetine
			* Fluoxetine
			* Fluvoxamine
			* Mirabegron
			* Paroxetine
			* Quinidine
			* Sertraline
			* Terbinafine
		- CYP450 3A4 inducers
			* Carbamazepine
			* Enzalutamide
			* Mitotane
			* Phenytoin
			* Rifampin
			* St. John’s wort
		- CYP450 3A4 inhibitors
			* Aprepitant
			* Atazanavir
			* Boceprevir
			* Cimetidine
			* Ciprofloxacin
			* Clarithromycin
			* Clotrimazole
			* Cobicistat
			* Conivaptan
			* Crizotinib
			* Cyclosporine
			* Diltiazem
			* Dronedarone
			* Erythromycin
			* Fluconazole
			* Fluvoxamine
			* Fosemprenavir
			* Grapefruit
			* Holkira Pak
			* Indinavir
			* Imatinib
			* Itraconazole
			* Ketoconazole
			* Idelalisib
			* Nefazodone
			* Nelfinavir
			* Netupitant
			* Posaconazole
			* Ritonavir
			* Technivie
			* Telaprevir
			* Telithromycin
			* Tofisopam
			* Troleandomycin
			* Verapamil
			* Veikira Pak
			* Voriconazole
	+ Agents that could ameliorate/mask EPS or OMD symptoms
		- Propranolol
		- Amantadine
		- Anticholinergics
			* Diphenhydramine
			* Benzotropine
			* Trihexyphenidyl
		- Benzodiazepines
			* Lorazapam
			* Alprazolam
			* Clonazepam
			* Diazepam
		- VMAT2 inhibitors
			* Valbenazine
			* Tetrabenazine
			* Deutetrabenazine

Legend: This list includes only agents that are classified as moderate or strong CYP450 inhibitors or inducers. Moderate is defined as ≥ 2 to < 5-fold increase in exposure, or 50% to 80% decrease in clearance of substrate. Strong is defined as ≥ 5-fold increase in exposure, or >80% decrease in clearance of substrate

Resources:

1. Cytochrome P450 Drug Interactions. PL Detail-Document #320506. May 2016. Copyright © 2016 by Therapeutic Research Center. Stockton, CA 95219.
2. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. U.S. Food and Drug Administration, Silver Spring, MD. Last updated: 11/14/2017. Accessed at: https://www.fda.gov/drugs/developmentapprovalprocess/development resources/druginteractionslabeling/ucm093664.htm